Mission Wealth Management LP increased its position in  Pfizer Inc. (NYSE:PFE – Get Rating) by 12.5% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 94,566 shares of the biopharmaceutical company’s stock after acquiring an additional 10,494 shares during the quarter. Mission Wealth Management LP’s holdings in Pfizer were worth $4,846,000 at the end of the most recent quarter.

Other large investors also recently modified their holdings of the company. Vanguard Group Inc. raised its stake in shares of  Pfizer by 1.1% during the third quarter. Vanguard Group Inc. now owns 493,584,761 shares of the biopharmaceutical company’s stock worth $21,599,270,000 after acquiring an additional 5,139,634 shares in the last quarter.  Charles Schwab Investment Management Inc. increased its stake in shares of  Pfizer by 13.2% in the first quarter. Charles Schwab Investment Management Inc. now owns 59,828,849 shares of the biopharmaceutical company’s stock worth $3,097,341,000 after buying an additional 6,972,650 shares during the period.  Bank of New York Mellon Corp increased its stake in shares of  Pfizer by 0.6% in the third quarter. Bank of New York Mellon Corp now owns 56,659,179 shares of the biopharmaceutical company’s stock worth $2,479,407,000 after buying an additional 317,858 shares during the period.  Dimensional Fund Advisors LP increased its stake in shares of  Pfizer by 2.5% in the third quarter. Dimensional Fund Advisors LP now owns 41,242,414 shares of the biopharmaceutical company’s stock worth $1,804,896,000 after buying an additional 1,009,399 shares during the period.  Finally, Price T Rowe Associates Inc. MD increased its position in  Pfizer by 4.4% during the 3rd quarter. Price T Rowe Associates Inc. MD now owns 36,467,989 shares of the biopharmaceutical company’s stock valued at $1,595,840,000 after purchasing an additional 1,529,779 shares during the period. 67.62% of the stock is currently owned by institutional investors.

In related news, major shareholder Pfizer Inc bought 1,811,594 shares of the stock in a transaction on Friday, March 17th. The shares were acquired at an average price of $2.76 per share, for a total transaction of $4,999,999.44. Following the purchase, the insider now owns 5,952,263 shares of the company’s stock, valued at $16,428,245.88. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Company insiders own  0.05% of the company’s stock.

A number of research analysts have issued reports on PFE shares. Bank of America downgraded shares of Pfizer from a “buy” rating to a “neutral” rating and set a $60.00 price objective on the stock. in a research report on Wednesday, January 4th. StockNews.com began coverage on shares of Pfizer in a report on Thursday, March 16th. They set a “buy” rating on the stock. Wells Fargo & Company dropped their target price on shares of Pfizer from $50.00 to $44.00 and set an “equal weight” rating on the stock in a report on Friday, March 17th. Berenberg Bank  set a $40.00 target price on shares of Pfizer in a report on Tuesday, February 7th. Finally, SVB Leerink dropped their target price on shares of Pfizer from $49.00 to $48.00 and set a “market perform” rating on the stock in a report on Wednesday, February 1st. Eight research analysts have rated the stock with a hold rating and six have assigned  a buy rating to the company’s stock. According to data from MarketBeat, the company  has a consensus rating of “Hold” and an average target price of $49.80.

Shares of Pfizer stock opened at $40.55 on Wednesday. The company has a debt-to-equity ratio of 0.34, a current ratio of 1.22 and a quick ratio of 1.00. The stock has a market cap of $228.88 billion, a price-to-earnings ratio of 7.40, a PEG ratio of 1.39 and a beta of 0.64. The firm’s 50-day moving average is $41.36 and its 200 day moving average is $45.36. Pfizer Inc. has a 1 year low of $39.23 and a 1 year high of $54.93.

Pfizer (NYSE:PFE – Get Rating) last posted its earnings results on Tuesday, January 31st. The biopharmaceutical company reported $1.14 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.03 by $0.11. The business had revenue of $24.30 billion for the quarter, compared to analysts’ expectations of $24.40 billion. Pfizer had a net margin of 31.27% and a return on equity of 42.03%. The business’s revenue for the quarter was up 1.9% compared to the same quarter last year. During the same quarter in the prior year, the business earned $1.08 EPS.  Sell-side analysts anticipate that  Pfizer Inc. will post 3.3 EPS for the current fiscal year.

Pfizer Inc is a research-based global biopharmaceutical company. It engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases.

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE – Get Rating).

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.